Direction of evolution in the bio-therapeutics market diverges with an emphasis on downsizing.
The biotherapeutics market grows larger each year, with no signs of attenuation. In 2008, the top biologics, Enbrel, Remicade, and Rituxan, each recorded over $5 billion in sales. The primary indications for approved protein therapeutics to date have been various...